Compare WAT & MKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAT | MKL |
|---|---|---|
| Founded | 1958 | 1930 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Property-Casualty Insurers |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 26.0B |
| IPO Year | 1995 | 1986 |
| Metric | WAT | MKL |
|---|---|---|
| Price | $379.10 | $2,030.30 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 1 |
| Target Price | $395.00 | ★ $2,025.00 |
| AVG Volume (30 Days) | ★ 503.3K | 46.3K |
| Earning Date | 02-12-2026 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.82 | N/A |
| EPS | 10.88 | ★ 142.27 |
| Revenue | $3,105,638,000.00 | ★ $16,210,307,000.00 |
| Revenue This Year | $7.96 | N/A |
| Revenue Next Year | $6.32 | N/A |
| P/E Ratio | $34.88 | ★ $14.30 |
| Revenue Growth | ★ 6.90 | N/A |
| 52 Week Low | $275.05 | $1,621.89 |
| 52 Week High | $417.10 | $2,207.59 |
| Indicator | WAT | MKL |
|---|---|---|
| Relative Strength Index (RSI) | 43.86 | 36.38 |
| Support Level | $367.12 | $2,008.67 |
| Resistance Level | $401.10 | $2,057.60 |
| Average True Range (ATR) | 9.58 | 38.73 |
| MACD | -2.21 | -4.29 |
| Stochastic Oscillator | 34.14 | 30.26 |
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.
Markel's primary business is property and casualty insurance. The company focuses primarily on specialty lines, ranging from areas such as executive liability to commercial equine insurance. The acquisition of Alterra in 2013 added substantial reinsurance operations, which now account for a little over 10% of premiums. The company uses capital generated by its insurance operations to buy noninsurance operations in diverse areas, such as bakery equipment manufacturing and residential homebuilding.